EW

Edwards Lifesciences
D

EW

Arincen78/100B

Edwards Lifesciences balance sheet 1999–2026

Edwards Lifesciences had 4.64B USD in cash and short-term investments on 30 September 2026, against total debt of 704.50M USD: net cash of 3.94B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
3.11B2.94B3.05B1.13B769.00M862.80M1.18B1.18B714.10M818.30M930.10M
Short-term investments
1.53B1.29B930.70M500.50M446.30M604.00M219.40M337.80M242.40M519.20M341.00M
4.64B4.23B3.98B1.63B1.22B1.47B1.40B1.52B956.50M1.34B1.27B
Cash growth
+20.89%+6.31%+143.50%+34.35%-17.15%+4.58%-7.54%+58.59%-28.49%+5.22%+3.79%
Receivables
937.80M912.10M727.40M828.10M699.10M664.90M602.80M599.10M537.30M479.30M414.60M
Inventory
1.16B1.13B1.09B903.50M875.50M726.70M802.30M640.90M607.00M554.90M396.60M
Other current assets
358.40M338.80M374.40M542.50M195.90M237.10M208.20M168.00M131.80M116.90M111.80M
Total current assets
7.25B6.74B6.29B4.04B3.10B3.18B3.09B2.98B2.29B2.53B2.24B
Property, plant and equipment
1.96B1.91B1.78B1.68B1.73B1.64B1.49B1.14B867.50M679.70M580.00M
Long-term investments
262.60M773.90M307.90M583.90M1.24B1.83B801.60M585.50M506.30M567.00M532.10M
Goodwill and intangibles
3.11B2.90B2.95B1.54B1.45B1.49B1.50B1.50B1.46B1.59B830.90M
Goodwill
1.95B1.77B1.78B1.15B1.16B1.17B1.17B1.17B1.11B1.13B626.10M
Intangible assets
1.16B1.13B1.18B399.40M285.20M323.60M331.40M336.50M343.20M468.00M204.80M
Other non-current assets
633.60M234.90M732.40M774.30M299.10M110.80M119.60M101.80M33.60M108.90M123.20M
Total assets
14.14B13.70B13.06B9.36B8.29B8.50B7.24B6.49B5.32B5.70B4.51B
Accounts payable
199.70M227.50M197.40M186.60M201.90M204.50M196.50M180.40M134.00M116.60M97.10M
Deferred revenue
0.0027.20M53.70M0.000.000.000.000.000.000.000.00
Short-term debt
0.0024.50M0.000.000.000.000.000.000.00598.00M0.00
Other current liabilities
191.40M874.50M442.70M530.20M305.00M342.70M290.50M338.90M434.00M349.10M234.10M
Total current liabilities
1.58B1.81B1.51B1.20B1.02B1.03B893.90M902.40M876.60M1.40B532.50M
Long-term debt
598.80M598.30M597.70M597.00M596.30M595.70M595.00M594.40M593.80M438.40M822.30M
Other non-current liabilities
926.60M865.00M810.60M786.20M797.60M969.60M1.10B784.10M712.90M851.80M536.20M
Lease obligations, current
24.90M0.0023.40M22.90M25.50M25.50M27.20M25.50M0.000.000.00
Lease obligations, long-term
80.80M82.60M78.90M65.20M69.50M69.10M72.70M58.90M0.000.000.00
Total liabilities
3.18B3.36B2.99B2.64B2.49B2.67B2.66B2.34B2.18B2.70B1.89B
Common stock and paid-in capital
662.30M658.70M654.80M650.50M646.30M642.00M636.40M218.10M215.20M212.00M242.60M
Retained earnings
15.17B14.24B13.17B8.99B7.59B6.07B4.57B3.74B2.69B2.00B3.91B
Accumulated other comprehensive income
-220.20M-238.30M-244.50M-242.80M-254.90M-157.70M-161.10M-156.00M-138.50M-132.70M-198.40M
Shareholders' equity
10.86B10.34B10.00B6.65B5.81B5.84B4.57B4.15B3.14B2.99B2.62B
Minority interest
100.40M0.0064.50M69.40M0.000.000.000.000.000.000.00
704.50M705.40M700.00M685.10M691.30M690.30M694.90M678.80M593.80M1.04B822.30M
Net cash
3.94B3.52B3.28B947.70M524.00M776.50M707.70M838.10M362.70M301.10M448.80M
Working capital
5.67B4.93B4.78B2.84B2.07B2.15B2.20B2.08B1.41B1.13B1.71B
Book value per share
18.8017.6516.6810.919.309.257.246.524.904.624.01
Tangible book value
7.75B7.44B7.05B5.11B4.36B4.34B3.07B2.64B1.69B1.40B1.79B
Tangible book value per share
13.4112.7011.768.386.986.884.864.152.632.162.74
Current ratio
4.603.724.183.383.033.083.463.312.611.814.21
Debt to equity
0.060.070.070.100.120.120.150.160.190.350.31

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Edwards Lifesciences's cash and debt

Source: Financial Modeling Prep